Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29048961 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2CA14CA12TSHRALDH1A1 | |
| SCHEMBL7249667 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2CA14CA12TSHRALDH1A1 | |
| SCHEMBL29066116 | 0.86 | ALDH1A1 (0.45) | SMN1; SMN2CA14TSHRALDH1A1 | |
| SCHEMBL29066112 | 0.86 | ALDH1A1 (0.45) | SMN1; SMN2CA14TSHRALDH1A1 | |
| SCHEMBL1928704 | 0.82 | NAAA (0.35) | SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL2664131 | 0.81 | — | — | |
| SCHEMBL7580898 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2CA14CA12TSHRALDH1A1 | |
| SCHEMBL35974 | 0.81 | — | — | |
| SCHEMBL16377936 | 0.81 | — | — | |
| SCHEMBL12972068 | 0.78 | TSHR (0.33) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180334441-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-10017482-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170066733-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-9499503-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9102639-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150210658-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-8623895-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120270803-A1 | Mitotic Kinesin Inhibitors and Methods of Use Thereof | ARRAY BIOPHARMA, INC. | 2012-10-25 | — | — | US | disclosed |
| US-8236825-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-1809280-B1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2011-09-07 | — | — | EP | disclosed |
| US-20110201651-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2011-08-18 | — | — | US | disclosed |
| US-7956073-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-7449486-B2 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080182992-A1 | Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents | ARRAY BIOPHARMA, INC. | 2008-07-31 | — | — | US | disclosed |
| EP-1809280-A2 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006044825-A2 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201651-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | SMN1; SMN2 1336/4885CA14 3519/4885CA12 3624/4885 |
| US-20150210658-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | SMN1; SMN2 1336/4885CA14 3519/4885CA12 3624/4885 |
| US-20080182992-A1 | Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents | KIF5B, KIF2C, KIFC1 | SMN1; SMN2 2399/4885CA14 3271/4885CA12 3087/4885 |
| US-20180334441-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF18B, KIF18A | SMN1; SMN2 2963/4885CA14 3345/4885CA12 3614/4885 |
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | KIF5B, KIF2C, KIFC1 | SMN1; SMN2 1447/4885CA14 2493/4885CA12 2475/4885 |
| US-10017482-B2 | Mitotic kinesin inhibitors and methods of use thereof | KIF5B, KIF18B, KIF18A | SMN1; SMN2 2963/4885CA14 3345/4885CA12 3614/4885 |
| US-20120270803-A1 | Mitotic Kinesin Inhibitors and Methods of Use Thereof | KIF5B, KIF2C, KIFC1 | SMN1; SMN2 1336/4885CA14 3519/4885CA12 3624/4885 |
| US-20170066733-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF18B, KIF18A | SMN1; SMN2 2963/4885CA14 3345/4885CA12 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.